This article is more than 5 years old. Information may no longer be current.

Pathway may predict treatment resistance in breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AACR Molecular Diagnostics in Cancer Therapeutic Development

The inhibition of Src signaling may be a useful method to treat patients with breast cancer who have become resistant to treatment, according to data presented at the Third American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Philadelphia.

Christina Coughlin, MD, PhD, medical director and global medical monitor for clinical research and development at Wyeth Pharmaceuticals, said that Src pathway activation appears to be a robust prognostic marker in women with breast cancer. “It tells us how well the patients is, or is not, going to survive,” she said.

Coughlin presented data from a study conducted to examine quantitative tissue microarray sampling in 650 patient samples. In a subset of 57 patients with triple-negative breast cancer, Coughlin and colleagues identified a high level of Src activation. These patients had a significant decrease in OS. In another subset of patients with either ER or PR expression, Src pathway activation predicted poor prognosis.

Coughlin and colleagues plan to further evaluate the role of Src pathway and Src inhibition in an upcoming phase-2 trial. – by Leah Lawrence

For more information:

• Coughlin CM. #PL03. Presented at: the Third AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development; Sept. 22-25, 2008; Philadelphia.